NCT01510756 - Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

May 31, 2014

Study Completion Date

December 31, 2014

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG

Sorafenib

Sorafenib 400mg orally twice daily will be administered for three cycles (1 cycle = 28 days). Subjects without significant toxicity or progressive disease may elect to continue treatment for a total of twelve cycles.

Trial Locations (1)

92093

UCSD Medical Center, La Jolla